/ATXS
ATXS Stock - Astria Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$12.83+0.94%
+$0.12 (+0.94%) • Dec 19
87
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.87
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+35.1%upside
Target: $17.33
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ATXS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$12.70 – $12.96
TARGET (TP)$17.33
STOP LOSS$11.80
RISK/REWARD1:4.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.08
52W High$13.29
52W Low$3.56
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-111,558,000 | $-83,030,000 | $-53,503,000 | $-194,976,000 | $-37,435,000 |
| Net Income | $-94,260,000 | $-72,891,000 | $-51,834,000 | $-194,912,000 | $-37,300,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.68 | $-2.42 | $-3.55 | $-24.58 | $-12.20 |
Company Overview
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
80%
Hold / Neutral
1
20%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
4 Bullish1 Neutral/Bearish
Price Targets
$29
Average Target
↑ 127.6% Upside
Now
$18
Low
$29
Average
$47
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 12th 2025 | Cantor Fitzgerald | Downgrade | Neutral | - |
| September 17th 2025 | H.C. Wainwright | Reiterated | Buy | $20← $16 |
| April 29th 2025 | Cantor Fitzgerald | Initiation | Overweight | $47 |
| January 31st 2025 | JMP Securities | Initiation | Mkt Outperform | $26 |
| July 29th 2024 | TD Cowen | Initiation | Buy | $35 |
| March 28th 2023 | Evercore ISI | Initiation | Outperform | $18 |
Earnings History & Surprises
ATXSBeat Rate
50%
Last 18 quarters
Avg Surprise
-4.4%
EPS vs Estimate
Beats / Misses
9/8
1 met exactly
Latest EPS
$-0.55
Q4 2025
EPS Surprise History
Q1 24
-24.6%
$-0.86vs$-0.69
Q2 24
-8.6%
$-0.38vs$-0.35
Q3 24
-16.2%
$-0.43vs$-0.37
Q4 24
0.0%
$-0.42vs$-0.42
Q1 25
+2.2%
$-0.44vs$-0.45
Q2 25
-20.8%
$-0.58vs$-0.48
Q3 25
+6.6%
$-0.57vs$-0.61
Q4 25
-34.1%
$-0.55vs$-0.41
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 10, 2026 | $-0.54 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.41 | $-0.55 | -34.1% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.61 | $-0.57 | +6.6% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.48 | $-0.58 | -20.8% | ✗ MISS |
Q1 2025 | Mar 11, 2025 | $-0.45 | $-0.44 | +2.2% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.42 | $-0.42 | 0.0% | = MET |
Q3 2024 | Aug 12, 2024 | $-0.37 | $-0.43 | -16.2% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.35 | $-0.38 | -8.6% | ✗ MISS |
Q1 2024 | Mar 4, 2024 | $-0.69 | $-0.86 | -24.6% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-0.51 | $-0.63 | -23.5% | ✗ MISS |
Q3 2023 | Aug 7, 2023 | $-0.50 | $-0.45 | +10.0% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.51 | $-0.40 | +21.6% | ✓ BEAT |
Q1 2023 | Mar 22, 2023 | $-0.74 | $-0.72 | +2.7% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.92 | $-0.87 | +5.4% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-1.04 | $-0.86 | +17.3% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.73 | $-1.18 | -61.6% | ✗ MISS |
Q1 2022 | Mar 10, 2022 | $-0.61 | $-0.73 | -19.7% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.92 | $-0.61 | +33.7% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $-1.82 | $-1.26 | +30.8% | ✓ BEAT |
Latest News
Cantor Fitzgerald Downgrades Astria Therapeutics to Neutral
➖ NeutralBenzinga•Nov 12, 2025, 07:06 PM
Astria Therapeutics Q3 EPS $(0.55) Misses $(0.41) Estimate, Sales $706.000K.
📉 NegativeBenzinga•Nov 12, 2025, 01:06 PM
Astria Therapeutics ALPHA-STAR Phase 1b/2 Study Evaluating Navenibart Monoclonal Antibody Inhibitor In Hereditary Angioedema Participants Shows Robust Attack Rate Reduction, Favorable Safety, Tolerability Profile
📈 PositiveBenzinga•Nov 6, 2025, 01:14 PM
Astria Therapeutics To Present Final Results From ALPHA-STAR Phase 1b/2 Trial Of Navenibart In People Living With HAE At ACAAI Annual Scientific Meeting
📈 PositiveBenzinga•Oct 31, 2025, 12:06 PM
HC Wainwright & Co. Downgrades Astria Therapeutics to Neutral
📉 NegativeBenzinga•Oct 16, 2025, 10:47 AM
Wedbush Downgrades Astria Therapeutics to Neutral, Lowers Price Target to $13
📉 NegativeBenzinga•Oct 15, 2025, 03:15 PM
JMP Securities Downgrades Astria Therapeutics to Market Perform
📉 NegativeBenzinga•Oct 15, 2025, 11:18 AM
Jefferies Downgrades Astria Therapeutics to Hold, Lowers Price Target to $13
📉 NegativeBenzinga•Oct 14, 2025, 06:18 PM•Also:
BioCryst to buy Astria Therapeutics for $13 per share (update)
📈 PositiveSeeking Alpha•Oct 14, 2025, 11:58 AM•Also:
Trading Halt: Halt status updated at 7:15:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Oct 14, 2025, 11:15 AM
BioCryst to Acquire Astria Therapeutics for Mix Of Cash And stock At Implied Value Of $13/Share
➖ NeutralBenzinga•Oct 14, 2025, 11:02 AM•Also:
Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Oct 14, 2025, 10:55 AM
Astria Therapeutics Initiates Phase 3 ORBIT-EXPANSE Trial of Navenibart For HAE, Announced Earlier Today
📈 PositiveBenzinga•Oct 8, 2025, 02:09 PM
Astria Therapeutics To Present New Data On Its Drug Candidate Navenibart At 2025 HAEi Regional Conference EMEA In Rome, Italy
📈 PositiveBenzinga•Oct 3, 2025, 12:04 PM
Astria Therapeutics Begins Opening Clinical Trial Sites In EU And May Begin Screening Participants For Phase 3 ALPHA-ORBIT Trial Of Navenibart For HAE Treatment
📈 PositiveBenzinga•Oct 2, 2025, 12:06 PM
HC Wainwright & Co. Maintains Buy on Astria Therapeutics, Raises Price Target to $20
📈 PositiveBenzinga•Sep 17, 2025, 03:46 PM
Cantor Fitzgerald Reiterates Overweight on Astria Therapeutics, Maintains $49 Price Target
📈 PositiveBenzinga•Sep 17, 2025, 02:12 PM
ATXS stock has given up its prior loss. Astria Therapeutics shares were trading lower.
➖ NeutralBenzinga•Sep 17, 2025, 01:42 PM
Astria Therapeutics shares are trading lower. The company announced initial results from the Phase 1a trial of STAR-0310 in healthy subjects.
📉 NegativeBenzinga•Sep 17, 2025, 12:52 PM
Astria Therapeutics Releases Initial Phase 1a Trial Results For STAR-0310 With Drug Showing Best-In-Class Half-Life Of Up To 68 Days Supporting Twice-Yearly Dosing, Demonstrated Durable Cytokine Inhibition, And Was Well-Tolerated With No ADCC-Related Side Effects
📈 PositiveBenzinga•Sep 17, 2025, 12:07 PM
Frequently Asked Questions about ATXS
What is ATXS's current stock price?
Astria Therapeutics, Inc. (ATXS) is currently trading at $12.83 per share. The stock has moved +0.94% today.
What is the analyst price target for ATXS?
The average analyst price target for ATXS is $17.33, based on 1 analyst.
What sector is Astria Therapeutics, Inc. in?
Astria Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ATXS's market cap?
Astria Therapeutics, Inc. has a market capitalization of $0.73 billion, making it a small-cap company.
Does ATXS pay dividends?
No, Astria Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARVN
Arvinas, Inc.
$11.68
Mkt Cap: $0.8B
AVBP
ArriVent BioPharma, Inc. Common Stock
$22.01
Mkt Cap: $0.9B
DAWN
Day One Biopharmaceuticals, Inc.
$9.24
Mkt Cap: $0.9B
DNA
Ginkgo Bioworks Holdings, Inc.
$8.10
Mkt Cap: $0.4B
ERAS
Erasca, Inc.
$3.45
Mkt Cap: $1.0B
IOVA
Iovance Biotherapeutics, Inc.
$2.48
Mkt Cap: $0.8B
MBX
MBX Biosciences, Inc. Common Stock
$30.42
Mkt Cap: $1.0B
MGTX
MeiraGTx Holdings plc
$8.03
Mkt Cap: $0.6B
REPL
Replimune Group, Inc.
$9.88
Mkt Cap: $0.8B
VALN
Valneva SE
$8.07
Mkt Cap: $0.7B
Explore stocks similar to ATXS for comparison